Prolonged wakefulness induces experience-dependent synaptic plasticity in mouse hypocretin/orexin neurons

Yan Rao, … , Tamas L. Horvath, Xiao-Bing Gao


Sleep is a natural process that preserves energy, facilitates development, and restores the nervous system in higher animals. Sleep loss resulting from physiological and pathological conditions exerts tremendous pressure on neuronal circuitry responsible for sleep-wake regulation. It is not yet clear how acute and chronic sleep loss modify neuronal activities and lead to adaptive changes in animals. Here, we show that acute and chronic prolonged wakefulness in mice induced by modafinil treatment produced long-term potentiation (LTP) of glutamatergic synapses on hypocretin/orexin neurons in the lateral hypothalamus, a well-established arousal/wake-promoting center. A similar potentiation of synaptic strength at glutamatergic synapses on hypocretin/orexin neurons was also seen when mice were sleep deprived for 4 hours by gentle handling. Blockade of dopamine D1 receptors attenuated prolonged wakefulness and synaptic plasticity in these neurons, suggesting that modafinil functions through activation of the dopamine system. Also, activation of the cAMP pathway was not able to further induce LTP at glutamatergic synapses in brain slices from mice treated with modafinil. These results indicate that synaptic plasticity due to prolonged wakefulness occurs in circuits responsible for arousal and may contribute to changes in the brain and body of animals experiencing sleep loss.

Find the latest version:
https://jci.me/32829/pdf
Prolonged wakefulness induces experience-dependent synaptic plasticity in mouse hypocretin/orexin neurons

Yan Rao,1 Zhong-Wu Liu,1,2 Erzsebet Borok,1 Rebecca L. Rabenstein,3 Marya Shanabrough,1 Min Lu,1 Marina R. Picciotto,1,4,5 Tamas L. Horvath,1,4,5 and Xiao-Bing Gao1

1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut, USA.
2Department of Neurobiology, Yanyang Medical College, Shiyan, Hubei, People’s Republic of China.
3Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
4Department of Neurobiology, and 5Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Sleep is a natural process that preserves energy, facilitates development, and restores the nervous system in higher animals. Sleep loss resulting from physiological and pathological conditions exerts tremendous pressure on neuronal circuitry responsible for sleep-wake regulation. It is not yet clear how acute and chronic sleep loss modify neuronal activities and lead to adaptive changes in animals. Here, we show that acute and chronic prolonged wakefulness in mice induced by modafinil treatment produced long-term potentiation (LTP) of glutamatergic synapses on hypocretin/orexin neurons in the lateral hypothalamus, a well-established arousal/wake-promoting center. A similar potentiation of synaptic strength at glutamatergic synapses on hypocretin/orexin neurons was also seen when mice were sleep deprived for 4 hours by gentle handling. Blockade of dopamine D1 receptors attenuated prolonged wakefulness and synaptic plasticity in these neurons, suggesting that modafinil functions through activation of the dopamine system. Also, activation of the CAMP pathway was not able to further induce LTP at glutamatergic synapses in brain slices from mice treated with modafinil. These results indicate that synaptic plasticity due to prolonged wakefulness occurs in circuits responsible for arousal and may contribute to changes in the brain and body of animals experiencing sleep loss.

Introduction

Sleep is a natural process that allows mammals to preserve energy; it facilitates development, and results in recuperation of the nervous system (1, 2). It is still unclear how the central nervous system responds to the increasing pressure resulting from the demand to keep awake during compulsory or voluntary sleep loss. Neuronal changes are likely to be important for overcoming the transition from the waking state to sleep but are also likely to contribute to the well-documented effects of sleep loss on the mammalian brain (3–5). It is clear that the activity of particular groups of neurons in wake-promoting centers increases during normal waking states as well as during sleep deprivation (SD), as demonstrated by increased spike firing, expression of c-Fos, and expression of a large spectrum of genes in these neurons (6–9); however, the fundamental question of how the demand for staying awake is translated into the increased activity and gene expression in these wake-promoting neurons remains unanswered.

Among the brain regions orchestrating the regulation of the sleep-wake cycle, the lateral hypothalamus (LH) has long been suggested to be a center responsible for arousal and maintenance of wakefulness (10). It is clear that a specific group of neurons expressing the neuropeptide hypocretin (also called orexin) in the LH promote wakefulness (11–13). Anatomically, hypocretin/orexin-expressing neurons receive and integrate inputs from many brain areas and send nerve fibers to major arousal centers in the brain (13, 14). The concentration of hypocretin/orexin in the cerebrospinal fluid and the action potential firing in hypocretin/orexin neurons fluctuate with the behavioral state of animals during the day (15–20). Consistent with its role in promoting alertness and arousal/wakefulness, the hypocretin/orexin system has been demonstrated to be highly plastic and easily activated upon challenge with stressors (21, 22). There is also recent evidence that hypocretin/orexin neurons are required for wakefulness and attention during SD (9); however, the adaptive changes underlying the ability of hypocretin/orexin neurons to drive prolonged wakefulness and respond to the increased demands for arousal have not been elucidated.

It is clear that excitatory synapses undergo long-term potentiation (LTP) as a result of coordinated activation. In addition, LTP appears to be a ubiquitous mechanism through which the brain makes adaptive changes in neuronal circuitry in response to demands from the external environment (23), such as learning a new skill (24) or adapting to a behavioral change (25). In this study we demonstrate that experience-dependent long-term plasticity takes place at glutamatergic synapses on hypocretin/orexin neurons during prolonged exposure to wakefulness in animals, consistent with the fact that glutamatergic synaptic transmission on hypocretin/orexin neurons provides a major excitatory input to these neurons and is essential to the functioning of the hypocretin/orexin system (22, 26, 27). Our data indicate that prolonged exposure to wakefulness leads to experience-dependent synaptic plasticity, including LTP at synapses on arousal/wakefulness-promoting neurons, which are required to keep functioning in order to maintain sufficient alert and wakefulness during long-term sleep loss.
Results

Prolonged wakefulness induces experience-dependent plasticity in hypocretin/orexin neurons. Modafinil (diphenylmethyl-sulfonyl-2-acetamide) is approved by the FDA for the treatment of narcolepsy and many other conditions (28, 29). Modafinil significantly enhances vigilance, alertness, and wakefulness in patients, with limited potential for addiction and without anxiogenic effects (28–30). The enhancement of wakefulness by modafinil occurs at the

Figure 1
LTP of excitatory synapses on hypocretin/orexin neurons following an acute exposure to prolonged wakefulness. (A) Modafinil (100 mg/kg) induces a long-lasting increment of locomotor activity in mice. Each point represents averaged beam breaks within a block of 5 minutes from all animals in each group during our experiments. The arrow indicates injection of modafinil or saline. (B) Sample traces of mEPSCs recorded in hypocretin/orexin neurons from saline- and modafinil-treated mice. (C) Mean frequency of mEPSCs recorded in hypocretin/orexin neurons from saline- or modafinil-treated mice. (D–F) Cumulative probability of the amplitude of mEPSCs recorded in all neurons from saline- and modafinil-treated mice 0, 1, and 2 hours after the injection of saline or modafinil. *P < 0.05, Student’s t test. (G and H) Relative contributions of AMPARs and NMDARs on evoked EPSCs recorded in hypocretin/orexin neurons from mice treated with saline and modafinil. *P < 0.05, Student’s t test.
expense of slow-wave and paradoxical sleep, probably as a result of increasing the dopaminergic (DA) tone through the blockade of the dopamine transporter (31, 32).

In the current study, male C57BL/6 mice were administered modafinil (100 mg/kg, i.p.) or saline, and locomotor activity (saline: n = 5, modafinil: n = 5) was measured during the light portion of the light-dark cycle as an indicator of wakefulness. Treatment of mice with modafinil induced a significant increase in locomotor activity lasting for 2 hours (Figure 1A), as demonstrated by a significant effect of treatment (F_{1,26} = 3.024; P < 0.01, repeated measures ANOVA). The absence of sleep in modafinil-treated compared with saline-treated mice throughout the experiment was confirmed by visual observation. Saline-treated mice spent a considerable amount of time sleeping in the testing cages, resulting in a significant decline in beam breaks throughout the experiment. In accord with previous results reported by Edgar and Seidel demonstrating that modafinil increased wake time but did not increase locomotor activity above the level expected for normal waking animals (33), the results reported here show that acute exposure to modafinil can induce long-lasting wakefulness in mice, as has been shown in rats and hamsters (32, 33). The acute effect of modafinil is reversible, since the locomotor activity of modafinil-treated mice returned to baseline levels the next day (data not shown).
We then tested the effect of a single episode of prolonged wakefulness during the normal sleep period on glutamatergic synaptic transmission in hypocretin/orexin neurons, since these neurons are thought to be the target of modafinil treatment (34). Miniature excitatory postsynaptic currents (mEPSCs) were recorded in hypocretin/orexin neurons (identified by the expression of GFP under the control of a selective hypocretin/orexin promoter) in brain slices taken from mice sacrificed 0, 1 or 2 hours after administration of modafinil or saline.

Changes in the frequency of mEPSCs are thought to result from modification of the presynaptic component of synaptic transmission, while changes in the amplitude of mEPSCs indicate alterations in the postsynaptic component (25, 35). The frequency of mEPSCs recorded immediately after the application of modafinil was 5.67 ± 0.78 Hz (n = 10), which was comparable to that recorded in slices from saline-treated mice (5.72 ± 0.69 Hz; n = 10; P > 0.05, Student’s t test). In contrast, the frequency of mEPSCs 1 hour after modafinil treatment was 9.08 ± 1.56 Hz (n = 17), while it was 5.54 ± 0.70 Hz (n = 17) in control mice (P < 0.05, Student’s t test). The frequency of mEPSCs 2 hours after treatment was 7.84 ± 0.72 Hz (n = 29) and 5.91 ± 0.88 Hz (n = 29) in slices from modafinil- and saline-treated mice, respectively (P < 0.05, Student’s t test) (Figure 1, B and C).

The cumulative probability curves for the amplitude of mEPSC events recorded 0, 1 and 2 hours after treatment in slices from control and modafinil-treated mice were plotted (Figure 1, D–F). The amplitude of mEPSCs was significantly increased 1 and 2 hours after modafinil treatment (P < 0.01, Kolmogorov-Smirnov test; Figure 1, E and F), whereas there was no significant difference between saline- and modafinil-treated mice immediately after modafinil administration (Figure 1D).

The ratio of synaptic currents carried by α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptors to those carried by NMDA glutamate receptors (AMPAR/NMDAR ratio) increases persistently during LTP (25, 36, 37). We measured the relative contributions of AMPAR and NMDAR to evoked excitatory postsynaptic currents (EPSCs) in hypocretin/orexin neurons from control and saline mice. Evoked EPSCs were recorded under voltage clamp at +40 mV in the absence and then presence of the selective NMDAR antagonist dl-2-amino-5-phosphonovaleric acid (AP5) as has been described (25). As shown in Figure 1, G and H, the AMPAR/NMDAR ratio recorded in hypocretin/orexin neurons from control and saline mice was 3.50 ± 0.23, n = 10; saline: 2.63 ± 0.29, n = 10; P < 0.05, Student’s t test).

These data suggest that prolonged wakefulness resulting from acute modafinil treatment induces LTP at excitatory synapses on hypocretin/orexin neurons, since application of modafinil directly to hypothalamic slices from normal mice does not induce any change.
experience-dependent plasticity would also develop in hypocretin/orexin neurons after chronic exposure to modafinil-induced prolonged wakefulness. Male C57BL/6 mice were habituated to locomotor testing cages once daily for 3 days. Following habituation, modafinil (20 mg/kg; n = 8) or saline (n = 8) was administered once daily for 7 days, and locomotor activity (indicating wakefulness during the light portion of the cycle) was measured. The minimal effective dose in mice reported in previous studies was used to avoid a ceiling effect in this experiment (30). Mice showed increased locomotor activity upon the first exposure to modafinil (main effect of day [F1,9 = 2.242; P < 0.05]) and the increment lasted as long as 2 hours (data not shown). Repeated modafinil administration resulted in a sensitization of the locomotor response with a main effect of treatment ([F1,11 = 15.049; P < 0.01] and a day-by-treatment interaction ([F1,9 = 2.262; P < 0.01]. Modafinil-treated mice showed significantly elevated locomotor activity on day 10 compared with the response to modafinil on day 4 (the first treatment; 1-way repeated ANOVA, P < 0.05). These data suggest that neuronal plasticity takes place in circuitry mediating modafinil-induced wakefulness (Figure 2A).

One day after completion of the 7-day treatment with modafinil or saline, the frequency of mEPSCs recorded in hypocretin/orexin neurons in slices was significantly greater (P < 0.05, Student’s t test; Figure 2, B and C) in slices from modafinil-treated mice (9.49 ± 1.35 Hz; n = 15) than in slices from control mice (6.24 ± 0.66 Hz; n = 18). In addition, the amplitude of mEPSC events was greater in neurons from modafinil-treated mice (50.7 ± 3.72 pA; n = 15) than in neurons from control mice (37.4 ± 1.85 pA; n = 18; Figure 2D); the cumulative probability of mEPSC amplitude obtained from modafinil-treated compared with control mice was significantly shifted to the right (P < 0.001, Kolmogorov-Smirnov test; Figure 2E). Finally, the AMPAR/NMDAR ratio of evoked EPSCs was modestly (not significantly) increased in neurons from modafinil-treated mice (3.92 ± 0.40; n = 14) compared with neurons from saline-treated mice (3.15 ± 0.26; n = 14) (P < 0.05, Student’s t test).

We next confirmed that anatomical changes consistent with synaptic plasticity occurred following repeated modafinil administration by measuring the number of asymmetric synapses on hypocretin/orexin-containing cell bodies using a previously reported method (22, 38). Unbiased ultrastructural analysis revealed a significant elevation in the number of asymmetric synapses on hypocretin/orexin perikarya in modafinil-treated mice (saline: 17.58 ± 1.97 boutons per 100-μm membrane length, n = 10; modafinil: 26.84 ± 2.85 boutons per 100-μm membrane length, n = 10; P < 0.05; Figure 2, F and G).

To confirm that prolonged wakefulness induces experience-dependent plasticity in hypocretin/orexin neurons, we examined the synaptic strength of glutamatergic synapses on hypocretin/orexin neurons following an episode of SD. Hypocretin-GFP mice were deprived of sleep for 4 hours by gentle handling as reported previously (9). Immediately after completion of the 4-hour SD, the frequency of mEPSCs recorded in hypocretin/orexin neurons was significantly increased (P < 0.05, Student’s t test; Figure 3B) in SD mice (9.75 ± 0.57 Hz; n = 28) as compared with control mice (6.34 ± 0.57 Hz; n = 28). In addition, the amplitude of mEPSCs was greater (P < 0.05, Student’s t test; Figure 3C) in neurons from SD mice.
Activity-dependent synaptic plasticity occurs in hypocretin/orexin neurons. We tested the ability of forskolin to induce LTP in hypocretin/orexin neurons to determine the mechanisms underlying the synaptic potentiation resulting from prolonged wakefulness. Bath application of forskolin, an activator of adenyl cyclase, induces LTP at all synapses on neurons in the hippocampus (42–45). The forskolin-induced LTP (For-LTP) is PKA dependent, and the PKA cascade is right downstream to the activation of the D1 dopamine receptor (39, 43, 44). Bath application of forskolin for 10 minutes induced a long-lasting potentiation of spike firing in hypocretin/orexin neurons (Figure 5). This potentiation persisted for the duration of the experiment (more than 1 hour; n = 5; Figure 5A). For-LTP is dose dependent and can be observed at a concentration as low as 1 μM (Figure 5B). In slices pretreated with a membrane-permeable PKA inhibitor, KT5720 (20 μM), For-LTP of spike frequency was largely blocked (116.7% ± 15.4% of baseline; n = 7; P > 0.05; Figure 5C). Forskolin (50 μM) also induced LTP of mEPSC frequency in hypocretin/orexin neurons (196.7% ± 11.5% of baseline 30 minutes after washout of forskolin; n = 5; P < 0.05, Student’s t test; Figure 6, A and B). The mean amplitude of mEPSCs was also significantly potentiated by forskolin (125.2% ± 11.5% of baseline; n = 5; P < 0.01, Student’s t test; Figure 6C), without significant changes in rise time, decay time, or half-width of events (data not shown). There was also a rightward shift in the cumulative distribution of mEPSC amplitude 30 minutes after removal of forskolin (Kolmogorov-Smirnov test, P < 0.001; Figure 6C, right), suggesting that elevating cAMP levels results in LTP of glutamatergic synaptic transmission in hypocretin/orexin neurons at both pre- and postsynaptic sites.

To confirm that cAMP acts postsynaptically in hypocretin/orexin neurons to induce For-LTP, we included PKI 

mice (28.32 ± 1.61 pA; n = 28) than in neurons from control mice (23.64 ± 1.52 pA; n = 28); the cumulative probability of mEPSC amplitude obtained from SD mice was significantly shifted to the right compared with control mice (P < 0.001, Kolmogorov-Smirnov test; Figure 3D). Finally, the AMPAR/NMDAR ratio of evoked EPSCs was significantly increased in neurons from SD mice (3.61 ± 0.58; n = 7) compared with neurons from control mice (2.2 ± 0.23; n = 7) (P < 0.05, Student’s t test; Figure 3, E and F).

It has been suggested that the DA system is involved in modafinil-induced wakefulness (29, 31) and that D1 receptors are necessary for stimulation of hypocretin/orexin neurons in the LH (39, 40).

Systemic application of the selective D1 receptor antagonist SCH 23390 [R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride] blocks the D1 receptor-mediated effect of cocaine on synaptic strength in DA neurons (41). As shown in Figure 4, A and B, pretreatment with SCH 23390 (0.5 mg/kg) 30 minutes before the application of modafinil (100 mg/kg) significantly attenuated the ability of modafinil to stimulate locomotor activity (P < 0.05; saline: 37.1 ± 16.6, n = 6; modafinil: 525.3 ± 143.5, n = 5; SCH 23390 plus modafinil: 145.0 ± 32.5, n = 5; Figure 4B). In addition, the frequency of mEPSCs in hypocretin/orexin neurons recorded 1 hour after modafinil treatment was significantly potentiated in mice treated with modafinil only (control mice: 4.55 ± 0.38 Hz, n = 15; modafinil: 6.59 ± 0.53 Hz, n = 16) but not in mice treated with SCH 23390 plus modafinil (4.85 ± 0.58 Hz; n = 14; P < 0.05, ANOVA; Figure 4B). In contrast, the cumulative probability of mEPSC amplitude obtained from mice treated with SCH 23390 plus modafinil compared with control mice was significantly shifted to the right (P < 0.001, Kolmogorov-Smirnov test; Figure 4D, solid gray line), just as in mice treated with modafinil alone (P < 0.001, Kolmogorov-Smirnov test; Figure 4D, dotted line). Thus, pretreatment with the D1 receptor antagonist attenuated modafinil-induced prolonged wakefulness, and this may have been due to the depression of potentiation of mEPSC frequency in hypocretin/orexin neurons.

Figure 5
Forskolin induces a long-lasting potentiation of spike generation in hypocretin/orexin neurons. (A) Time course of For-LTP of action potentials in hypocretin/orexin neurons. Representative traces of spikes (action currents) recorded extracellularly before and 1 hour after the application of forskolin were taken at the times indicated on the graph. The black bar indicates the application of forskolin. (B) Bar graph indicates the dose-dependence of For-LTP in hypocretin/orexin neurons. Percentage changes in spike frequency recorded 30 minutes after the withdrawal of forskolin at 4 different doses are shown. *P < 0.05; **P < 0.01. (C) Time course of spike frequency indicates that inhibition of PKA eliminates For-LTP of action potentials in hypocretin/orexin neurons (P > 0.05, paired Student’s t test).
presence of PKI$_{6-22}$, forskolin did not alter the mean amplitude of mEPSCs (Figure 6E; 98.57% ± 8.83% of baseline; $n = 5$; $P > 0.05$; 30 minutes after removal of forskolin), and the cumulative probability of the mEPSC amplitude showed little change ($P > 0.05$, Kolmogorov-Smirnov test; Figure 6E, right). In contrast, the frequency of mEPSCs was still significantly potentiated by forskolin 30 minutes after the removal of drug (233.3% ± 26.25% of baseline; $P < 0.01$; Figure 6D).

For-LTP is occluded in hypocretin/orexin neurons in modafinil-treated mice. If in vivo modafinil treatment induces PKA-dependent synaptic plasticity, we would expect that induction of For-LTP in slices from modafinil-treated mice should be occluded. Hypothalamic slices were prepared 2 hours after acute administration of modafinil or saline. Forskolin (50 μM) induced a comparable increment in mEPSC frequency in modafinil-treated mice (194.95% ± 12.83% of baseline; $n = 6$) compared with that in saline-treated mice (208.9% ± 9.25% of baseline; $n = 6$; $P > 0.05$, Student’s $t$ test; Figure 7A). Similarly, mEPSC amplitude was increased in both groups of mice (Kolmogorov-Smirnov test; Figure 7, C and D). However, the potentiation of amplitude of mEPSCs was significantly smaller in mice acutely exposed to modafinil (109.94% ± 4.08%; $n = 6$) than in control mice (123.18% ± 2.67%; $n = 6$; $P < 0.05$, Student’s $t$ test; Figure 7B). In order to eliminate the possibility of a ceiling effect, we also tested a lower forskolin concentration (5 μM). The frequency of

![Figure 6](https://www.jci.org)  
LTP of glutamatergic synapses on hypocretin/orexin neurons elicited by application of forskolin. (A) Sample traces (left) and single events (right) of mEPSCs recorded in hypocretin/orexin neurons before and 30 minutes after the application of forskolin. (B) Time course of the averaged frequency of mEPSCs from all tested neurons is shown on the left, and pooled data of the frequency of mEPSCs from all neurons before and 30 minutes after the application of forskolin are shown on the right. **$P < 0.01$. (C) Time course of the averaged amplitude of mEPSCs recorded in our experiments is shown on the left. Right: Cumulative probability of mEPSC amplitude recorded before (831 events) and 30 minutes after the application of forskolin (1,566 events) ($P < 0.001$, Kolmogorov-Smirnov test). (D) LTP of the frequency of mEPSCs induced by forskolin is intact in the presence of PKI$_{6-22}$ in the pipette solution. Left: Time course of mEPSC frequency during the postsynaptic application of PKI$_{6-22}$. Right: Pooled data of mEPSC frequency from all tested neurons before and 30 minutes after the application of forskolin. **$P < 0.01$, paired Student’s $t$ test. (E) LTP of mEPSC amplitude is blocked when PKI$_{6-22}$ is present in pipette solution. Left: Time course of mEPSC amplitude recorded in our experiments during the postsynaptic application of PKI$_{6-22}$. Right: Cumulative probability of mEPSC amplitude recorded before (469 events) and 30 minutes after the application of forskolin (1,100 events) when PKI$_{6-22}$ was applied to postsynaptic neurons ($P > 0.05$, Kolmogorov-Smirnov test).
mEPSCs recorded 30 minutes after the treatment of forskolin (5 μM) was significantly attenuated in hypocretin/orexin neurons from modafinil-treated mice (126.32% ± 14.16% of baseline; n = 6; Figure 7E) compared with those from control mice (168.03% ± 15.95% of baseline; n = 6; Figure 7E; P < 0.05, Student’s t test). The amplitude of mEPSCs returned to baseline 15 minutes after withdrawal of forskolin in modafinil-treated mice (P > 0.05, Kolmogorov-Smirnov test; Figure 7, F and H). In contrast, mEPSC amplitude remained elevated 30 minutes after withdrawal of forskolin in saline-treated mice (120.97% ± 7.87% of baseline; n = 6) but not in modafinil-treated mice (P > 0.05, Kolmogorov-Smirnov test). The Kolmogorov-Smirnov test of cumulative probability of mEPSC amplitude before and after forskolin treatment confirmed that forskolin significantly increased the amplitude of mEPSCs in slices from saline-treated mice (P < 0.001; Figure 8E) but not in slices from modafinil-treated mice (P > 0.05; Figure 8F).

Taken together, these data suggest that similar mechanisms underlie modafinil-induced, experience-dependent synaptic plasticity and For-LTP.

Discussion

Prolonged wakefulness at the expense of sleep results in beneficial (such as antidepressive) and adverse (such as cognitive impairment) effects (1, 3–5, 46); however, the fundamental neurobiological changes resulting from SD remain to be explored. Previ-
ous reports have suggested that hypocretin/orexin neurons are activated following modafinil treatment and SD (9, 34), but the mechanisms underlying adaptive changes in the activity of hypocretin/orexin neurons have not been examined. In this study we induced prolonged wakefulness in mice either by administering modafinil or by gently handling animals during the light phase, when mice are normally asleep. Previous data from rats and Syrian hamsters showed that in vivo administration of modafinil during the light phase prolonged wakefulness and reduced slow wave and paradoxical sleep (32, 33). Using modafinil could reduce the stress resulting from experimental manipulations leading to sleep loss. The results of this study provide the first evidence to our knowledge that experience-dependent synaptic plasticity takes place at glutamatergic synapses on hypocretin/orexin neurons during prolonged wakefulness. LTP at inputs to hypocretin/orexin neurons provides a mechanism for how wake-promoting centers maintain prolonged wakefulness during sleep loss.

A single administration of modafinil leads to an LTP-like potentiation of synaptic strength pre- and postsynaptically, which lasts for the duration of wakefulness (Figure 1). Chronic administration of modafinil induced synaptic plasticity in hypocretin/orexin neurons, as measured by increased synaptic strength and increased number of synapses on hypocretin/orexin-containing perikarya (Figure 2), suggesting that prolonged wakefulness over several days leads to reorganization of excitatory synapses on hypocretin/orexin neurons. This type of synaptic reorganization has also been observed following food deprivation (22). Consistent with these adaptive changes induced by modafinil treatment, a single episode of SD led to a similar potentiation of synaptic strength at glutamatergic synapses on hypocretin/orexin neurons in this study (Figure 3), suggesting that experience-dependent synaptic plasticity in hypocretin/orexin neurons may underlie prolonged wakefulness induced by physiological and environmental factors.

It has already been shown that modafinil enhances the DA tone in the brain and that the DA system regulates (enhances in most cases) the activity of hypocretin/orexin neurons (31, 39, 40). Our experiments with a selective D1 receptor antagonist, SCH 23390, suggest that D1 receptor activation contributes to expression of the experience-dependent synaptic plasticity observed in this study. Pretreatment with SCH 23390 significantly attenuated modafinil-induced prolonged wakefulness and depressed the presynaptic potentiation of glutamatergic synapses on hypocretin/orexin neurons (Figure 4). There has been ample evidence that SD is associated with an increased DA tone in the brain (46, 47). Therefore, enhanced activity of the DA system during prolonged wakefulness resulting from SD may also lead to experience-dependent synaptic plasticity in hypocretin/orexin neurons reported here.

It is suggested in this study that LTP can be elicited following intensive activation of neuronal ensembles centered on hypocretin/orexin neurons (Figure 6). Occlusion of LTP has been observed following regimens that might be expected to result in experience-dependent synaptic plasticity, such as training in a novel task or administration of drugs of abuse (24, 25). The occlusion of For-LTP in hypocretin/orexin neurons by modafinil treatment indi-
cates that the molecular and cellular machinery responsible for LTP (in particular the PKA-dependent pathways downstream to D1 receptor activation) contribute to experience-dependent synaptic plasticity following prolonged wakefulness (Figures 7 and 8). It is noteworthy that the attenuation of For-LTP was greater in slices from animals treated chronically with modafinil than in slices from animals treated acutely (Figures 7 and 8), indicating that full expression of LTP was established only after chronic treatment. These results are consistent with the behavioral experiments, which showed that locomotor activity was enhanced by acute modafinil administration but continued to increase over several days of administration (Figure 2A). For-LTP was not completely occluded in slices from modafinil-treated mice, perhaps because synaptic plasticity resulting from wakefulness due to exposure to modafinil only occurs at a subset of synapses, whereas For-LTP occurs at all synapses on hypocretin/orexin neurons.

Our data further suggest the involvement of signaling pathways mediated through other neurotransmitters in experience-dependent plasticity reported in this study. Blockade of D1 receptor activation did not completely abolish modafinil-induced prolonged wakefulness (Figure 4). The potentiation of the postsynaptic component of glutamatergic synapses still existed after the modafinil treatment in the presence of the D1 receptor blockade. These results are consistent with the involvement of norepinephrine- and histamine-mediated pathways in modafinil-induced effects (34, 48). In addition, it is also worth investigating whether the lack of complete occlusion of For-LTP in mice exposed to prolonged wakefulness was due to the involvement of other signaling pathways. There has been a report of a more robust effect of modafinil in hypocretin/orexin-KO mice (49). We believe that this might be due to the compensatory effect of other wakefulness-promoting systems in the brain in the absence of the hypocretin/orexin system. Modafinil may work with the remaining wakefulness-promoting systems in hypocretin/orexin-KO mice to exert its function. These systems may participate in modafinil-induced plasticity in hypocretin/orexin neurons.

The potentiation of excitatory inputs to hypocretin/orexin neurons reported here would have a substantial impact on neuronal activity in the LH and ultimately on a wide range of behaviors related to prolonged wakefulness. In particular, this potentiation may represent the neural basis for synaptic homeostasis occurring during prolonged wakefulness. Since wakefulness-promoting centers other than the hypocretin/orexin system are also likely to be activated during prolonged wakefulness, it is reasonable to propose that experience-dependent synaptic plasticity similar to what we observed here may develop in other brain areas as well.

It has recently been hypothesized that there are cycles of potentiation and depression of excitatory synapses of cortical neurons during the daily sleep-wake cycle, through which neural functions could be reset and memory could be consolidated (2). This intriguing theory of the function of sleep in synaptic homeostasis is supported by cycles of expression of various genes (many of which play important roles in the regulation of synaptic transmission) across the sleep-wake cycle in rats (8, 50) and the elevated phosphorylation level of GluR1 in sleep-deprived rats (51). In the current study, we provide direct evidence to support the notion that the strength of excitatory synapses may change depending on the level of activity of neuronal ensembles participating in sleep-wake regulation (2).

While sleep regulates synaptic activity in brain regions such as the cortex (2), adaptive changes in synaptic strength (experience-dependent synaptic plasticity) may also contribute to the maintenance of the behavioral state. This may be particularly important for neuronal systems necessary for homeostatic mechanisms involved in arousal, such as hypocretin/orexin neurons and other wakefulness-promoting centers.

In summary, from an evolutionary point of view, the experience-dependent potentiation of excitatory synapses on hypocretin/orexin neurons during prolonged wakefulness would be adaptive, since the hypocretin/orexin system is critical for positive energy balance (52), which is required to maintain a sufficient energy supply for animals to interact with the environment. It is therefore intriguing to hypothesize that repeated, prolonged wakefulness resulting from sleep restriction (deprivation) could lead to significant adverse effects (such as unbalanced energy consumption) as a result of experience-dependent synaptic plasticity in brain areas involved in both arousal and energy balance.

Methods
All animal procedures were performed in accordance with NIH Guide for the Care and Use of Laboratory Animals and were approved by the Yale University Animal Care and Use Committee.

Modafinil treatment and locomotor activity. Locomotor activity was measured as previously described (53). Male C57BL/6 mice (6–8 weeks old; Jackson Laboratory) were group housed and maintained on a 12-hour light/12-hour dark cycle (lights on at 7:00 am), with food and water available ad libitum. All modafinil injections and behavioral tests were performed between 10 am and 5 pm. Modafinil (Sigma-Aldrich) was dissolved in 1% DMSO in sterile water. All animals were habituated to the locomotor apparatus for 3 days. This was followed by a single modafinil (acute treatment, 100 mg/kg, i.p.) or saline injection or 7 days of modafinil (chronic treatment, 20 mg/kg, i.p.) or saline administration. On each test day, animals were habituated to the testing room for 30 minutes before being put into locomotor activity cages and were further habituated to the test boxes for 15 minutes; after habituation, animals received either a modafinil or a saline injection, and locomotor activity was monitored for 2 hours (acute administration) or 30 minutes (chronic exposures). To test the involvement of the D1 receptor in modafinil-mediated effects, a selective D1 antagonist, SCH 23390 (Tocris Bioscience), was administered (i.p.) 30 minutes before the application of modafinil.

Locomotor activity was measured in clear plastic cages (46 cm × 24 cm × 20 cm) between 2 rows of Opto-Max sensors (Columbus Instruments) containing 16 photocells, each 2.54 cm apart. Another locomotor activity apparatus (MED Associates) was used for some experiments. Locomotor activity was assessed by measuring the number of beam breaks recorded during each 5-minute block across the session.

SD. SD was achieved as reported previously (9). Male C57BL/6 mice (6 weeks old) expressing GFP exclusively in hypocretin/orexin neurons were housed individually and maintained on a 12-hour light/12-hour dark cycle, with food and water available ad libitum. Mice were divided into 2 groups (control and SD), and the experiment was performed in the home cages. Mice in the SD group were SD for 4 hours (8:00 am to 12:00 pm) by gentle touching with a small, soft paintbrush upon eye closure, while mice in the control group were allowed to undergo normal sleep and waking from 8:00 am to 12:00 pm. All mice were habituated to the presence of the experimenter and the paintbrush for 3 days prior to the SD experiment. After the experiments, all mice were sacrificed for electrophysiological studies.

Electrophysiology. Transgenic mice expressing GFP exclusively in hypocretin neurons were used to prepare coronal hypothalamic slices in this study (26, 35). For electrophysiological recordings after 1 bout of modafinil treatment or SD, hypothalamic slices were prepared from mice sacrificed 0, 1, or 2 hours after administration of modafinil or saline or immediately after...
SD. For electrophysiological recordings after repeated modafinil treat-
ment, hypalamic slices were prepared from mice sacrificed 1 day after
the completion of a 7-day treatment. The electrophysiological recordings
were performed in a blinded manner after the above treatments. Male mice
(14–21 days old) were anesthetized with ether and then decapitated.
The brains were rapidly removed and immersed in a cold (4°C) oxygenated,
high-sucrose solution containing (in mM): sucrose 220, KCl 2.5, NaHPO
4.1, NaHCO3, 26, CaCl2, 1, MgCl2, 6 and glucose 10 (pH 7.3 with NaOH).
Coronal slices (300 μm thick) were cut on a vibratome and maintained in
a holding chamber with artificial cerebrospinal fluid (ACSF; bubbled with
5% CO2 and 95% O2) containing (in mM): NaCl 124, KCl 3, CaCl2, 2, MgCl2
2, NaHPO4, 2.3, NaHCO3, 26, glucose 10 (pH 7.4 with NaOH). After a
1-hour recovery period, slices were transferred to a recording chamber and
were constantly perfused with ACSF (33°C) at a rate of 2 ml/min.

Extracellular recordings were made with a glass electrode filled with
ACSF (resistance ≥ 1 MΩ) with a multicomp 780A amplifier (Axon Instru-
tments). A loose seal was formed (resistance = 10–30 MΩ) when the micro-
pipette touched the surface of an identified hypocretin-GFP neuron. After
a 10-minute control was recorded, drugs were applied to the recording
chamber by bath application.

Whole-cell voltage-clamp recording (at 60 mV or +40 mV) was per-
fomed using low-resistance (3–4 MΩ) pipettes. The composition of the
pipette solution was as follows (in mM): K-gluconate (or Cs-gluconate)
135, MgCl2, 2, HEPES 10, EGTA 1.1, Mg-ATP 2, and Na2-phosphocreatin
10, Na2-GTP 0.3, pH 7.3 with KOH. After a gigahm (GΩ) seal and whole-
cell access were achieved, the series resistance was partially compensated
by the amplifier. Both input resistance and series resistance were moni-
tored throughout the experiments. Only those recordings with a stable
series resistance (≤20 MΩ) and input resistance were accepted. mEPSCs
were recorded under voltage clamp at −60 mV in the presence of tetrodo-
toxin (TTX; 1 μM; Alomone Labs Ltd.) and bicuculline (30 μM; Sigma-
Aldrich). To monitor evoked EPSCs, the stimulating electrode was placed
laterally to the recorded neurons at least 125 μm away. Evoked EPSCs
recorded in hypocretin/orexin neurons under voltage-clamp at +40 mV
in the presence of picrotoxin (50 μM; Sigma-Aldrich) contained both
AMPA and NMDA components, and AMPAR-carried EPSC was obtained
by applying AP5 (50 μM; Sigma-Aldrich) to the recorded neurons.
Then NMDAR-carried EPSC was determined by subtracting the AMPA
component from the whole EPSC recorded before the application of AP5.
To induce LTP, forskolin (Tocris Bioscience) was applied to recorded
neurons after a stable baseline of synaptic currents was obtained. PKA
inhibitor KT5720 (Sigma-Aldrich) was applied to the recording chamber
via bath application, and PKA inhibitor fragment 6-22 amide (PKI-22,
Sigma-Aldrich) was applied in the pipette solution.

All data were sampled at 3–10 kHz and filtered at 1–3 kHz with an Apple
Macintosh computer using Axograph 4.9 (Axon Instruments). Electrophys-
iological data were analyzed with Axograph 4.9 and plotted with KaleidaG-
raph 3.6 (Synergy Software) and Igor Pro 5.04 (WaveMetrics Inc.). Action
currents and miniature postsynaptic currents were detected and measured
with an algorithm in Axograph 4.9 (35). The frequency and mean amplitude
of mEPSC were normalized to baseline and expressed as mean ± SEM.

Ultrastructural analysis of hypocretin perikarya. The unbiased analysis
of synapse density on hypocretin/orexin cell bodies was performed as
described previously (22, 38). Briefly, the LH/perifornical region was dis-
sected from each brain, and the processing of the tissue for hypocretin
immunocytochemistry and electron microscopy were done as described
previously (22, 54). Hypocretin-immunolabeled cells with an equal immu-
noperoxidase density were studied from each group.

The analysis of synapses was performed in a double-blind fashion (22).
The synaptic counts were expressed as numbers of synapses on a mem-
brane length unit of 100 μm. For statistics, n represents the number of
neurons analyzed for each group. For each group, the mean number of
synapses was calculated from 10 hypocretin/orexin neurons. F test analy-
ses revealed significant homogeneity of variance within groups and sig-
nificant nonhomogeneity of variances between groups (e.g., control versus
modafinil-treated). Thus, for the intergroup multiple statistical compari-
sons, the Kruskal-Wallis 1-way nonparametric ANOVA test was applied.
The Mann-Whitney U test was used to determine the significance of differ-
ences between groups. A level of confidence of P < 0.05 was employed for
the statistical significance.

Acknowledgments

This study is supported by NIH grants DK070723 to X.-B. Gao;
DK060711, DK074386, AO22880, and NS041725 to T.L. Hor-
vath; and AA15632 to M.R. Picciotto. We thank Alex Hanxiang
Wang for technical and editorial assistance.

Received for publication May 29, 2007, and accepted in revised

Address correspondence to: Xiao-Bing Gao, Department of OB/
GYN, Yale University School of Medicine, 333 Cedar St., New
Haven, Connecticut 06520, USA. Phone: (203) 783-2340; Fax: (203)
737-1883; E-mail: xiao-bing.gao@yale.edu.

1. Siegel, J.M. 2005. Clues to the functions of mam-
2. Tononi, G., and Cirelli, C. 2006. Sleep function and
3. Rechtschaffen, A., Bergmann, B.M., Everson, C.A.,
deprivation in the rat: X. Integration and discus-
sion of the findings. Sleep. 12:68–87.
sleep fragmentation versus sleep deprivation.
6. Aston-Jones, G., and Bloom, F. 1981. Activity of
norepinephrine containing locus coeruleus neu-
rons in behaving rats anticipates fluctuations in
Neuronal gene expression in the waking state: a role
Extensive and divergent effects of sleep and wakeful-
9. Modirrousta, M., Mainville, L., and Jones, B.E.
2005. Orexin and MCH neurons express c-Fos dif-
erently after sleep deprivation vs. recovery and
21:2807–2816.
10. van Economo, C. 1931. Sleep as a problem of local
11. Lin, L., et al. 1999. The sleep disorder canine nar-
colepsy is caused by a mutation in the hypocretin
knockout mice: molecular genetics of sleep regulation.
13. de Lecea, L., and Sutcliffe, J.G. 2005. The hypo-
cretin and sleep. FEBS J. 272:5675–5688.
14. Yoshida, K., McCormack, S., Espana, R.A., Crock-
er, A., and Scammell, T.E. 2006. Afferents to the
tin-1 (orexin A) levels in rats across 24 hours and
hypocretin-1 (orexin A) levels in the rat in relation
to the light-dark cycle and sleep-wake activities.
regulation of hypocretin in a primate model: implica-
23:3555–3560.
18. Esterbrooke, I.V., et al. 2001. Fos expression in orex-
in neurons varies with behavioral state. J. Neurosci.
Discharge of identified orexin/hypocretin neu-rons across the sleep-waking cycle. J. Neurosci.
20. Milčekovský, B.Y., Kyashchenko, L.I., and Siegel, J.M.
2005. Behavioral correlates of activity in identified


